Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Ligand Pharmaceuticals Incorporated - Common Stock (NQ:LGND)

183.83 +2.18 (+1.20%)
Streaming Delayed Price Updated: 4:00 PM EST, Feb 13, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Ligand Pharmaceuticals Incorporated - Common Stock

< Previous 1 2 3 4 Next >
News headline image
Demystifying Ligand Pharmaceuticals: Insights From 10 Analyst Reviews ↗
 
Via Benzinga
News headline image
Arcellx And Legend Bio Trade Jabs In Multiple Myeloma. But Only One Pulls Ahead. ↗
The companies held competing events on Sunday to discuss their multiple myeloma treatments. 
Via Investor's Business Daily
News headline image
A Closer Look at 7 Analyst Recommendations For Ligand Pharmaceuticals ↗
 
Via Benzinga
News headline image
Critical Insights From Ligand Pharmaceuticals Analyst Ratings: What You Need To Know ↗
 
Via Benzinga
News headline image
Assessing Ligand Pharmaceuticals: Insights From 7 Financial Analysts ↗
 
Via Benzinga
News headline image
The Latest Analyst Ratings For Ligand Pharmaceuticals ↗
 
Via Benzinga
News headline image
Looking Into Ligand Pharmaceuticals's Recent Short Interest ↗
 
Via Benzinga
News headline image
Assessing Ligand Pharmaceuticals: Insights From 6 Financial Analysts ↗
 
Via Benzinga
News headline image
What 4 Analyst Ratings Have To Say About Ligand Pharmaceuticals ↗
 
Via Benzinga
News headline image
Earnings Scheduled For February 27, 2024 ↗
Companies Reporting Before The Bell • Gaotu Techedu (NYSE:GOTU) is expected to report quarterly loss at $0.07 per share on revenue of $100.49 million. 
Via Benzinga
News headline image
Stock Market Rally Begins After Global Rout; Palantir, Eli Lilly, Fortinet Jump: Weekly Review ↗
After Monday's panicked global sell-off, markets have calmed down. 
Via Investor's Business Daily
News headline image
LGND Stock Earnings: Ligand Pharmaceuticals Beats EPS, Beats Revenue for Q2 2024 ↗
LGND stock results show that Ligand Pharmaceuticals beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024. 
Via InvestorPlace
News headline image
Halozyme And Ligand — Two Leading Biotechs — Smash Quarterly Forecasts ↗
Halozyme and Ligand beat second-quarter expectations late Tuesday. But only one of the biotech stocks jumped. 
Via Investor's Business Daily
News headline image
3 Magnificent Growth Stocks to Buy Hand Over Fist ↗
Small-cap stocks could get a boost from the central bank's anticipated rate cuts in 2025. These three stocks may be a great way to get ahead of this catalyst. 
Via The Motley Fool
Topics Economy
News headline image
Ligand Pharmaceuticals's Earnings: A Preview ↗
 
Via Benzinga
News headline image
Where Ligand Pharmaceuticals Stands With Analysts ↗
 
Via Benzinga
News headline image
Analyst Expectations for Ligand Pharmaceuticals's Future ↗
 
Via Benzinga
News headline image
3 Must-Buy Biotech Stocks Before the Summer Rally Kicks Off ↗
With the innovation space possibly getting overstretched, these biotech stocks to buy could benefit from a sector rotation. 
Via InvestorPlace
News headline image
LGND Stock Earnings: Ligand Pharmaceuticals Beats EPS, Beats Revenue for Q1 2024 ↗
LGND stock results show that Ligand Pharmaceuticals beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024. 
Via InvestorPlace
News headline image
Don't Overlook These Top Medical Stocks As Q1 Earnings Approach ↗
While the tech sector has led the Q1 earnings season, investors shouldn’t overlook these top medical stocks. To that point, the growth and expansion of Ligand Pharmaceuticals, Oscar Health, and... 
Via Talk Markets
News headline image
7 Small-Cap Stocks for the Thinking Speculator ↗
While these small-cap stocks may be miles away from Wall Street’s spotlight, they’re compelling enough to deliver some big surprises. 
Via InvestorPlace
News headline image
Why Is Ligand Pharmaceuticals Stock Trading Higher Today? ↗
Ligand Pharmaceuticals beats Q4 2023 sales estimates at $28.1 million, with strong core Captisol and royalty figures. CEO Todd Davis highlights transformative 2023 and optimistic guidance for 2024. 
Via Benzinga
News headline image
Norwegian Cruise Line Posts Strong Sales, Joins Hims & Hers Health, Sterling Infrastructure And Other Big Stocks Moving Higher On Tuesday ↗
U.S. stocks were mixed, with the Dow Jones index falling around 100 points on Tuesday. 
Via Benzinga
Topics Stocks
News headline image
Why Helix Energy Solutions Shares Are Trading Lower By 11%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session ↗
Shares of Helix Energy Solutions Group, Inc. (NYSE: HLX) fell sharply during Tuesday’s session following weak earnings. 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Merck Highlights Data On New Vaccine, Compares 'Tolerability And Safety' To Pfizer's ↗
Merck & Co Inc (NYSE: MRK) released results from the STRIDE-3 Phase 3 trial evaluating V116, the company's investigational 21-valent  
Via Benzinga
News headline image
Ligand Pharma Updates Annual Guidance As It Spins Out Pelican Subsidiary ↗
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) entered into a merger agreement under which its subsidiary, Pelican Technology Holdings Inc, has become a wholly owned subsidiary of Primrose Bio... 
Via Benzinga
News headline image
Why Are Novan Shares Nosediving Today? ↗
Novan Inc (NASDAQ: NOVN) shares are trading lower after Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announced that it has offered to  
Via Benzinga
News headline image
3 Stocks That Smart Investors Should Be Flocking to Now ↗
Investors may want to detour away from the obvious trades and consider compelling top stocks for smart investors. 
Via InvestorPlace
News headline image
Viking Therapeutics Outperforms Expectations: Analyst Increases Price Target Following Successful VK2809 Trial ↗
Ligand Pharmaceuticals Incorporated's (NASDAQ: LGND) partner Viking Therapeutics Inc (NASDAQ: VKTX) announced positive topline results from its Phase 2b trial of VK2809 in  
Via Benzinga
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.